Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

115.91 -0.30 (-0.26%)

Official Closing Price Updated: 7:00 PM EDT, Mar 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

3 High-Yielding Dividend Stocks That Are Trading Near Their 52-Week Lows ↗

August 02, 2025

If you are looking for dividend stocks, a good place to start is with unloved stocks like these, with yields of up to 6.4%.

Via The Motley Fool

Topics Intellectual Property

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' ↗

August 01, 2025

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Via Benzinga

Topics Government

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today ↗

July 31, 2025

These stocks have all surged more than 1,000% since August 2020.

Via The Motley Fool

Topics Artificial Intelligence

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Merck & Co's Earnings Outlook ↗

July 28, 2025

Via Benzinga

P/E Ratio Insights for Merck & Co ↗

July 24, 2025

Via Benzinga

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns ↗

July 30, 2025

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove investor interest.

Via Benzinga

Topics Earnings

Why Merck Stock Slipped Today ↗

July 29, 2025

A change in full-year guidance by management wasn't particularly welcome.

Via The Motley Fool

Is Merck & Co Gaining or Losing Market Support? ↗

July 29, 2025

Via Benzinga

Why Merck (MRK) Shares Are Sliding Today

July 29, 2025

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.2% in the afternoon session after the company reported second-quarter financial results that missed revenue expectations and revealed a...

Via StockStory

Topics Artificial Intelligence Workforce

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗

July 29, 2025

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Via Benzinga

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges ↗

July 29, 2025

Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.

Via Benzinga

These S&P500 stocks are gapping in today's session ↗

July 29, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.

Via Chartmill

Merck’s Full Year Guidance Disappoints Investors But Retail Pins Hopes On $3B Cost-Cutting Plan ↗

July 29, 2025

The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said.

Via Stocktwits

Topics World Trade

Which S&P500 stocks are moving before the opening bell on Tuesday? ↗

July 29, 2025

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Via Chartmill

Merck Posts Q2 EPS Beat Revenue Slips ↗

July 29, 2025

Via The Motley Fool

Merck’s (NYSE:MRK) Q2 Earnings Results: Revenue In Line With Expectations

July 29, 2025

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was...

Via StockStory

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

July 29, 2025

From Merck & Co., Inc.

Via Business Wire

Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever ↗

July 28, 2025

If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.

Via The Motley Fool

Topics Lawsuit

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact ↗

July 28, 2025

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

Via Benzinga

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings ↗

July 28, 2025

Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.

Via Benzinga

3 Surprisingly Underrated Stocks to Buy Right Now ↗

July 28, 2025

These big pharma stocks arguably aren't receiving the respect they deserve.

Via The Motley Fool

Topics Intellectual Property

What To Expect From Merck’s (MRK) Q2 Earnings

July 27, 2025

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Via Benzinga

Topics Artificial Intelligence ETFs

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma ↗

July 25, 2025

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Via Benzinga

Merck & Co. Inc. (NYSE:MRK): A Strong Value Investment with Undervalued Potential ↗

July 25, 2025

Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors.

Via Chartmill

Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗

July 23, 2025

The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.

Via Investor's Business Daily

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock ↗

July 22, 2025

The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.

Via Investor's Business Daily

Merck Announces Fourth-Quarter 2025 Dividend

July 22, 2025

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.